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oenzyme Q10 and
tatins in Heart Failure
he Dog That Didn’t Bark*
. Michael Felker, MD, MHS
urham, North Carolina
Detective Gregory: “Is there any other point to which you would
wish to draw my attention?”
Holmes: “To the curious incident of the dog in the night-time.”
Detective Gregory: “The dog did nothing in the night-time.”
Holmes: “That was the curious incident.”
—Silver Blaze, Sir Arthur Conan Doyle (1)
oenzyme Q10 is an essential cofactor in mitochondrial
etabolism and may protect against oxidative stress. En-
ogenous coenzyme Q10 synthesis is blocked by 3-hydroxy-
-methylglutaryl-coenzyme A (HMG-coA) reductase in-
ibitors (statins). These facts have led to questions about
hether statin-induced depletion of coenzyme Q10 could be
mechanism for statin-induced myopathy, or more impor-
antly, whether depletion of coenzyme Q10 by statins could
ctually worsen heart failure. Supportive evidence for these
oncerns includes the known relationship between low
holesterol levels and poor outcomes in heart failure (2), as
ell as a prior publication in the Journal reporting that low
lasma coenzyme Q10 levels were an independent risk factor
or worsened outcomes in heart failure (3).
See page 1196
A Google search combining the search terms “statins,”
coenzyme Q10,” and “heart failure” results in thousands of
inks, many asserting a relationship between statin therapy,
oenzyme Q10 depletion, and heart failure outcomes. Many
uch sources recommend coenzyme Q10 supplementation
nd/or avoidance of statin drugs for patients with heart
ailure, and some even attribute the rising prevalence of
eart failure to the growing use of statins. Questions from
atients about coenzyme Q10 supplementation (sometimes
ccompanied by voluminous pages printed from the Inter-
et) are frequent in clinical practice.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Duke Clinical Research Institute, Durham, North Carolina. Dr. Felkers
as received research support from Roche Diagnostics, BG Medicine, and Cytoki-
etics; and consulting support from Corthera, Amgen, Cytokinetics, and XDX.In this issue of the Journal, McMurray et al. (4) present
he most robust data available to date analyzing the rela-
ionship between plasma coenzyme Q10 levels, statin ther-
py, and outcomes in patients with heart failure. In a
rospectively defined analysis requested by the Food and
rug Administration, these investigators examined plasma
oenzyme Q10 levels in 1,191 patients enrolled in the
ORONA (Controlled Rosuvastatin Multinational Study
n Heart Failure) trial, an international randomized trial of
osuvastatin versus placebo in patients with chronic heart
ailure of ischemic etiology. Notable strengths of this
nalysis include its prospective design, large sample size, the
andomized, double-blind nature of statin treatment, and
ystematic evaluation of outcomes with regard to both
uscle symptoms and cardiovascular events. Although clin-
cal trials typically enroll patients who are younger and have
ewer comorbidities than the broader heart failure popula-
ion, the CORONA study targeted and enrolled an older
opulation with ischemic heart failure, somewhat mitigat-
ng this potential limitation. This dataset creates a robust
pportunity to address 2 important questions regarding
oenzyme Q10 and statin therapy in heart failure.
s coenzyme Q10 a prognostic biomarker in heart failure?
n the CORONA study, lower coenzyme Q10 levels were
ssociated with several other markers of greater disease
everity, including older age, higher amino-terminal pro-B-
ype natriuretic peptide (NT-proBNP), lower ejection frac-
ion, and lower glomerular filtration rate. Although coen-
yme Q10 levels were associated with adverse outcomes in
nivariable analysis, a carefully constructed series of multi-
ariable models demonstrated no independent relationship
etween baseline coenzyme Q10 levels and a variety of
ardiovascular outcomes. These results stand in contrast to
reviously published findings examining the relationship
etween coenzyme Q10 and outcomes in heart failure (3).
s the authors argue convincingly in their discussion, the
ORONA dataset included many more patients and many
ore events, and thus had the ability to adjust for more
ovariates and provide more precise estimates of the
ndependent relationship between baseline variables and
utcomes. The data from the CORONA study suggest
hat while low coenzyme Q10 appears to be a marker of
reater disease severity, it is very unlikely to have utility as a
linically important prognostic biomarker in heart failure.
s there a clinically important link between coenzyme
10 levels and the effect of rosuvastatin on clinical
utcomes? The most notable findings from the analysis by
cMurray et al. (4) are the lack of a significant interaction
etween low coenzyme Q10 levels and the effect of rosuv-
statin on a variety of cardiovascular outcomes. Although
here were numerically higher numbers of events for rosu-
astatin compared to placebo in the lowest coenzyme Q10
ertile for most end points, these relationships did not reach
ominal statistical significance, whether analyzed within
ubgroups or based on coenzyme Q10-by-treatment inter-
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Coenzyme Q10 and Statins in Heart Failure October 5, 2010:1205–6ction terms. Although interaction tests generally have low
tatistical power, it is notable that only 1 of the 19 p values
enerated for either subgroup analysis within tertile 1 or the
nteraction across groups (Tables 3 and 4 of McMurray et
l. [4]) reach nominal statistical significance, about the same
requency (1 of 20) as would be anticipated by chance alone.
detailed breakdown by type of event showed no difference
n heart-failure-related deaths or hospitalizations for rosu-
astatin versus placebo, even in the lowest coenzyme Q10
ertile. Complaints of muscle pain were no more common
mong patients with low coenzyme Q10 levels, and there
as no significant difference in muscle symptoms between
atients treated with rosuvastatin or placebo.
Do these findings prove that there is no interaction
etween low baseline coenzyme Q10 levels and the effects of
osuvastatin? Given the logical challenges of “proving a
egative,” it may be preferable to say that these data strongly
uggest that any interactions between coenzyme Q10 and the
ffects of statin therapy in patients with ischemic heart
ailure are very unlikely to be clinically important. These
ndings also must be considered in the context of the overall
eutral results of the CORONA study (5) and the
ISSI-HF (Gruppo Italiano per lo Studio della Sopravvi-
enza nell’Infarto miocardico–Heart Failure) trial (6), nei-
her of which demonstrated a substantial beneficial effect of
tatin therapy on outcomes of patients with systolic heart
ailure. Despite these neutral studies of heart failure, statin
herapy remains indicated for a variety of patient groups that
verlap with heart failure, and these data from the
ORONA study clearly strengthen the evidence for the
afety of these drugs for such patients.
What about the therapeutic use of coenzyme Q10 sup-
lements, either as a treatment for heart failure generally or
s a therapy to address muscle-related side effects of statins?
either of these common questions from patients is ad-
ressed directly by the data from the CORONA study, and
uch questions about therapeutic efficacy can only be defin-
tively answered by appropriately designed clinical trials.
he efficacy and safety of micronutrients such as coenzyme
10 in heart failure remains unproven and continues to be a
ubject of debate (7). Similarly, a recent systematic review of
he data on coenzyme Q10 depletion and statin myopathy
id not find definitive evidence for either a causative role or
therapeutic benefit from coenzyme Q10 supplements (8).
iven the lack of association in the CORONA study, these
ata do not support an important role of coenzyme Q10 as
mediator of either myopathy symptoms or cardiovascular
utcomes in patients with heart failure. The coenzyme Q10
tory demonstrates the potential pitfalls of imputing causa-
ion from association. All putative biomarkers should be
xamined as to whether they are simply associated with
reater disease severity (“markers”) or, alternatively, play an Kmportant mechanistic role in the disease of interest (“me-
iators”). Coenzyme Q10 appears to be a marker, and
enerally only mediators make intuitive sense as targets for
ntervention.
Finally, the data from McMurray et al. (4) highlight the
otential for substudies of large clinical trials to address
mportant clinical questions. Multicenter clinical trials such
s CORONA represent a tremendous investment of time
nd resources on the part of investigators, study coordina-
ors, sponsors, and most importantly, patients, who agree to
articipate in human experimentation with the understand-
ng that this participation will help advance human health.
n the evolving era of personalized medicine, collection of
iologic samples (such as plasma and deoxyribonucleic acid)
hould not be seen as “ancillary,” but rather as a fundamental
spect of clinical trials in cardiovascular disease. Such a
ramework allows clinical trials to expand beyond answering
ot only the question “does it work?” but also “why (or why
ot)?” Like the dog that didn’t bark in Arthur Conan
oyle’s short story, these data from the CORONA study
re most notable for what is absent rather than what is
resent, and as such represent a “negative” study. Although
t is human nature to regard “finding something” with more
nterest than “finding nothing,” often the absence of find-
ngs may be of substantial importance. Just ask Sherlock
olmes.
eprint requests and correspondence: Dr. G. Michael Felker,
400 Pratt Street, Room 0311, Terrace Level, Durham, North
arolina 27705. E-mail: michael.felker@duke.edu.
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